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Successful wound care involves optimizing patient local and systemic conditions in conjunction with an ideal wound healing
environment. Many diﬀerent products have been developed to inﬂuence this wound environment to provide a pathogen-free,
protected, and moist area for healing to occur. Newer products are currently being used to replace or augment various substrates
in the wound healing cascade. This review of the current state of the art in wound-healing products looks at the latest applications
of silver in microbial prophylaxis and treatment, including issues involving resistance and side eﬀects, the latest uses of negative
pressure wound devices, advanced dressings and skin substitutes, biologic wound products including growth factor applications,
and hyperbaric oxygen as an adjunct in wound healing. With the abundance of available products, the goal is to ﬁnd the most
appropriate modality or combination of modalities to optimize healing.
1.Introduction
Theﬁeldofwoundcareseeminglycontainsasmanydiﬀerent
treatment options and modalities as the number of practi-
tioners caring for wounds. While many clinicians rely on and
obtain good results with older “tried and true” treatments,
there continues to be a constant ﬂow of new products and
technologies to add to the wound care armamentarium.
Some of these products are updated and improved variations
of previous treatments, while others are the result of entirely
new ﬁelds of study. As with any new product, oftentimes
the race to introduction into clinical use precedes adequate
controlled study, and the eﬃcacy is then deﬁned by clinical
experience. This can lead to unanswered questions regarding
appropriate use and indications.
This paper will discuss several new technologies in
burn and wound care. Silver dressings are time honored in
wound care, but new forms of delivery aim to increase the
eﬃcacy while minimizing side eﬀects. We will also review
some of the latest literature on emerging bacterial resistance
to these products. Negative pressure wound devices are
relatively new in wound caretreatment,and their indications
are continually expanding to encompass aspects of wound
managementthatpreviouslyhadveryfewoptions.Advanced
wound dressing products can help alter the wound envi-
ronment to optimize healing conditions. With the advent
of biosynthetics and tissue engineering, skin substitutes
are being created that not only provide novel eﬀective
temporary coverage of wounds, but are also changing the
paradigm of wound management. By supporting the wound
with growth factors and biologic substances, we can help
augment or modulate the wound healing process itself. And
ﬁnally hyperbaric oxygen treatment can provide additional
assistance to the above wound healing modalities, especially
in chronic wounds not responding to other treatment.
2. Silver
The use of silver to prevent and treat infection is both one
of the earliest forms of wound care, documented as early
as 69BC, and one of the latest technologies in the realm of2 Plastic Surgery International
antimicrobial prophylaxis. Because silver does have such a
favorable broad-spectrum coverage, especially in antibiotic-
resistant organisms, with little signiﬁcant toxicity, there have
been a number of new silver-containing wound products
developed to capitalize on its wound healing beneﬁts while
tailoring the delivery to the most eﬀe c t i v em e a n sw i t ht h e
fewest side eﬀects.
Regardless of the nature of the many silver-containing
products currently available, elemental silver requires ion-
ization for antimicrobial eﬃcacy [1]. The highly reactive
charged silver ion (Ag+) reacts by binding to negatively
charged particles such as proteins, DNA, RNA, and chloride
ions. While this is responsible for its antimicrobial proper-
ties, it also complicates delivery as the silver ions are readily
bound to proteins and chloride in the wound bed ﬂuid
[2]. Many delivery systems exist, with the key to the most
eﬀective product being one that can maintain an adequate
concentration of silver with long enough residual activity.
Introduced in 1968, silver sulfadiazine (Flammazine,
Silvadene) is silver complexed to various glycols and alcohols
and combined with an antibiotic, sulphadiazine [3]. While
this combination provides a theoretical advantage by includ-
ing an additional mechanism of action from the antibiotic,
it has been shown to have a higher rate of resistance
compared with silver nitrate (1% versus 0.5%) [4], as well
as impaired reepithelialization, pseudoeschar formation, and
bone marrow toxicity from the propylene glycol [5].
Nanocrystalline silver dressings were developed and
introduced in the late 1990s and are the latest forms of
silver wound dressings. These products were designed to
overcome some of the shortcomings of previous silver
dressings. The typical products currently in use contain two
layers of high-density polyethylene net sandwiching a layer
of rayon/polyester gauze [6] .T h eo u t e rl a y e ri sc o a t e dw i t ha
nanocrystalline (<20nm), noncharged form of silver (Ag0),
and the inner layer helps maintain a moist environment
for wound healing. Because the noncharged silver is less
reactive with negatively charged particles in the wound, it
is deactivated much more slowly and provides an initial
large bolus of silver followed by a sustained release into
the wound. Aside from a more consistent therapeutic dose
of silver, an additional beneﬁt of nanocrystalline dressings
is less frequent dressing changes, on the order of days as
compared to standard, twice daily dressing changes for silver
sulfadiazine and up to twelve times per day for silver nitrate.
This decreases patient discomfort as well as provides less
disruption to the healing wound bed.
Silver has a very broad spectrum of microbial coverage,
including yeast, fungi, mold, and even antibiotic-resistant
bacteria such as methicillin-resistant Staph aureus (MRSA)
and vancomycin-resistant enterococci (VRE) when used at
appropriate concentrations. Silver is a bactericidal material
that kills on contact by inhibiting the respiratory chain at
the cytochrome level, as well as, interfering with electron
transport [6], denaturing nucleic acids, inhibiting DNA
replication, and altering cell membrane permeability [5].
While bacterial resistance to silver is exceedingly low,
it has been reported in the literature since 1975 [7, 8].
This has mostly come from burn units using silver salts as
antiseptic agents. Identiﬁed silver-resistant strains include E.
coli, Enterobacter cloacae, Klebsiella pneumoniae, Acinetobac-
ter baumannii, Salmonella typhimurium, and Pseudomonas
stutzeri [7–10]. In fact a silver-resistant Salmonella species
caused the closure of the burn unit at Massachusetts General
Hospital after septicemia and death in three patients [11].
The challenge is to keep a high enough concentration
of agent with a long enough residual activity to prevent
developing resistance. The suggested concentration of silver
in any preparation is greater than 30 to 40mg/L to be
eﬀective. Traditional silver preparations, silver nitrate and
silver sulfadiazine, both are able to provide a high enough
initial concentration (3176mg/L and 3025mg/L, resp. [4]),
but have little to no residual activity. Silver nitrate must
be applied twelve times per day to maintain eﬀectiveness.
Nanocrystalline silver technology is able to more consistently
maintain adequate concentrations (at least 70mg/L) with
good residual activity, keeping levels elevated over longer
periods of time.
To demonstrate the eﬀectiveness of these dressings, Yin
et al. [12] compared between nanocrystalline silver, silver
sulfadiazine, and silver nitrate by inoculating each with
107 CFU of S. aureus. After one hour the nanocrystalline
dressing had fewer than 100 organisms remaining, whereas
the silver nitrate took 4 hours and silver sulfadiazine took
6 hours to achieve the same result. Wright et al. [13]
showed that nanocrystalline dressings killed MRSA in 30
minutes, whereas other silver preparations had no eﬀect.
They obtained similar results with VRE. Numerous other
studies have shown similar results, with overall time-for-
time higher MRSA clearance rates with nanocrystalline
silver versus silver sulfadiazine [14]; faster wound healing
times, reduced cellulitis, and reduced need for antibiotics
with nanocrystalline silver [15]; less burn wound sepsis
again with nanocrystalline silver [16]. Though these results
do appear very promising, Khundkar et al. [6] express a
word of caution. In their recent literature review comparing
nanocrystalline silver to other silver preparations, only 1 of
31 articles was rated as Level of Evidence 1 (randomized
controlled trial of suﬃcient size for narrow conﬁdence
interval), with the majority of articles LOE 5 (expert opinion
or based on bench research).
Silver concentrations lethal to bacteria can also cause
damagetohealthycells.Invitrostudiesonsilvernitrateshow
a negative impact on ﬁbroblasts [17]. Studies on nanocrys-
talline silver show inhibition of keratinocyte growth [18]a n d
delayinreepithelialization[19],leadingtorecommendations
against using topical silver as a dressing on cultured skin
grafts. Further in vitro studies have shown nanocrystalline
silver to be speciﬁcally toxic to cultured skin substitutes, with
cytotoxic eﬀects occurring within 1 day. However, in vivo
exposure of these cultured cells to nanocrystalline silver for
up to 1 week did not impair wound healing.
Overall silver is a very eﬀective modality for prevention
or treatment of infection over a wide variety of bacteria,
viruses,fungi,andmolds,withfewsideeﬀects.Thoughthere
are some reports of developing resistance, with continued
appropriateuseitshouldremaineﬀective against even multi-
antibiotic-resistant microorganisms.Plastic Surgery International 3
3. Negative PressureWound Devices
The ﬁrst paper describing the use of a negative pressure
wound device (NPWD) in a series of patients was published
thirteen years ago [20]. While the device itself has undergone
some minor advances in technology, the most signiﬁcant
changes have come from the indications for use. Advances in
the actual device include smaller size, allowing for portable
unitsforhomeuse,increasedabilitytoremovelargeamounts
of ﬂuid, the ability to instill ﬂuids in the wound for
continuous irrigation, reﬁnements in the foam with more
consistent pore sizes, diﬀerent sponge materials including
silver, and increased safety and alarm systems [21].
Acute wounds are now more frequently being treated
with NPWD closure. In patients with signiﬁcant comorbidi-
ties or other serious injuries, NPWDs can be used in large
soft-tissue injuries, contaminated wounds, and wounds with
compromised tissue [21]. The protocol is altered to include
more frequent dressing changes with serial debridement as
necessary. There are several descriptions of the sponge being
placed over vital structures such as vessels, nerves, viscera,
or even heart or lung [21, 22]. Ideally, muscle or soft tissue
should be placed between the structure and the sponge,
but if this is not possible Vaseline or silicone mesh should
be used. This allows simpliﬁed wound closure in critical
patients allowing the focus to shift to stabilizing the patient
for later deﬁnitive reconstruction with ﬂaps. One discovery
thathascomeaboutbytreatingacutewoundsinthismanner
is that the overall volume and dimensions of the wound
tend to decrease with NPWD closure, possibly allowing a
less complex reconstruction than would initially be required
[22]. Many complex wounds in stable patients are now being
temporized with NPWDs to allow a simpler reconstruction.
Enterocutaneous ﬁstulas were initially a contraindication
for NPWD closure. Some of these patients are now being
treated with NPWDs with good results. In published studies,
approximately two-thirds of forty reported patients had
closure of the ﬁstula with the device, albeit the majority of
these patients had low-output ﬁstulas [22]. Trauma patients
undergoing damage-control laparotomy and abdominal
compartment syndrome patients are also being temporized
by allowing an open abdomen with the NPWD in place.
This provides temporary coverage and, more importantly,
provides a mechanism for removal of intraabdominal con-
tamination and exudates while relieving visceral edema [23,
24]. These patients traditionally required large hernia repairs
with mesh, but with the NPWD, a high percentage are able
to be primarily closed.
Traumatic orthopedic injuries have seen bold advances
with the advent of NPWD closure. Signiﬁcant extremity
wounds were previously treated with wide debridement
of any questionable tissue with free ﬂaps being required
for immediate coverage. With the NPWD, debridement
is targeted to nonviable tissue, with the device providing
a sealed, protected, and moist environment that actively
removes edema and hematoma, which increases perfusion
and maximizes salvage of the zone of stasis. Serial debride-
ments are performed, with deﬁnitive reconstruction occur-
ring in a stable wound on an elective basis [25]. Exposed
Table 1: Advanced wound dressings.
Protective dressings Notes
Gauze Inexpensive; readily available
Impregnated gauze Nonadherent; preserves moisture
Antimicrobial dressings
Antibacterial ointments Reapply often to maintain
moisture
Iodine based Absorbent; not for use with thy-
roid disorders
Silver based Many forms; broad spectrum;
low resistance
Autolytic debridement
Films Occlusive; allows exchange of
gasses
Hydrocolloids Not for exudative or infected
wounds
Hydrogels Rehydrates to soften dry wounds
Chemical debridement
Papain/urea Availability issues in US
Collagenase Selective debridement
Absorbent dressings
Foam Absorbs moderate exudate
Hydrogels Absorbs minimal exudate
Hydroﬁbers Absorbs heavy exudate
Alginates Absorbs heavy exudate
tendon, bone, or joints are no longer a contraindication as
granulation tissue will form over these structures, allowing
a bed for skin grafting if necessary [26, 27]. Even inert
material such as orthopedic hardware, vascular synthetic
graft, or synthetic mesh will develop granulation tissue with
the NPWD [22]. These structures are ideally reconstructed
with protective ﬂaps, but skin grafting over this granulation
tissue is an option in patients that are not ﬂap candidates.
4.AdvancedDressings
Whileplaingauzeisstillthemostcommonlyuseddressingin
hospitals today, new wound understanding and technology
have produced advanced products that help the body
achieve the ideal moist, warm, protected wound healing
environment (Table 1). Plain gauze certainly has its place
as it is inexpensive, readily available, and appropriate for a
large number of wounds. Impregnated gauze improves upon
this by adding zinc, iodine, or petrolatum to help prevent
desiccation and provide nonadherent coverage.
The process of autolysis is important in wound care.
If an occlusive dressing is provided as a barrier to the
outside environment, the body’s own phagocytic processes
will provide debridement of wounds. These products range
f r o mo c c l u s i v eﬁ l m ss u c ha sT e g a d e r m ,w h i c ha r ep e r m e a b l e
to air and water vapor, but impermeable to ﬂuid and
microorganisms to hydrocolloids such as DuoDERM, which
are also occlusive but provide absorption of exudates in
addition to maintaining a moist environment for autolysis.4 Plastic Surgery International
For heavily exudative wounds, there are a range of absorptive
products including various hydrophilic foam dressings,
hydrogels, hydroﬁbers, and alginates, which can absorb up
to 20 times their weight. Though these products are more
expensive than traditional gauze, recent studies seem to
indicate an overall cost savings due to decreased labor costs:
advanced dressings typically are changed every 1 to 3 days, as
opposed to gauze, which is often changed multiple times per
day [28]. Additionally, faster healing times from advanced
dressings mean an overall decreased treatment period.
5. SkinSubstitutes
The advances in temporary and permanent coverage of
wounds have made signiﬁcant gains with advancing tech-
nology in biomaterials and tissue engineering. Burn wounds
are the major indication for these products. With advances
in burn resuscitation and critical care management, more
patients with signiﬁcant body surface area burns are sur-
viving, leading to the issue of coverage of large wounds.
Autograft is currently the preferred option, but in many
instances there is an insuﬃc i e n ta m o u n to ft i s s u ea v a i l a b l e
for grafting, or the patient’s condition precludes the use of
autograft. Allografts and xenografts can provide a temporary
coverage option, but they come with issues regarding
rejection, and possible disease transfer, availability, as well as
cultural and ethical considerations.
Bioengineered skin substitutes, both biosynthetic skin
substitutes and cultured autologous engineered skin, are
available to provide temporary or permanent coverage,
with the advantages of availability in large quantities and
negligible risk of infection or immunologic issues. The main
limitation of these products is their expense. We will brieﬂy
discuss currently available products and further discuss
some of these products that may confer an advantage over
autologous tissue in terms of potential for wound healing in
chronic wounds.
Biobrane is a temporary dressing composed of knitted
nylon mesh bonded to a thin silicone membrane and coated
with porcine polypeptides [29]. It is used in clean superﬁcial
and middermal depth burns or as coverage for donor sites
in split-thickness skin grafting. Studies have shown it to be
as eﬃcacious as silver sulfadiazine in wound healing without
the frequency of dressing changes [30].
TransCyte is a biosynthetic dressing of a semipermeable
silicone membrane on a nylon mesh coated with porcine
collagen and newborn human ﬁbroblast cells [29]. It is used
as a dressing in superﬁcial burns that do not require skin
grafting, or as a temporary cover for excised burns prior
to grafting. Several studies have shown it to be superior to
antibiotic creams or silver sulfadiazine in terms of healing
time, infections, and scar formation, especially on facial
burns [31, 32].
Dermagraft contains neonatal ﬁbroblasts on a bioab-
sorbable polyglactin mesh. The ﬁbroblasts produce der-
mal collagen, glycosaminoglycans, growth factors, and
ﬁbronectin to support wound healing [30]. It is a temporary
or permanent cover used for excised burn wounds as well as
venous ulcers and pressure ulcers [29]. Results show it to be
comparable to allograft for wound infection, healing time,
exudates, and graft take, with higher patient satisfaction
[33, 34].
Apligraf is composed of an epidermal layer of allogeneic
neonatal keratinocytes and ﬁbroblasts from neonatal fore-
skin on bilayered type I bovine collagen [29, 35] that is used
as an adjunct covering to autograft, providing accelerated
healing times [30]. It is also used alone in chronic wound
ulcers, showing increased healing times when compared to
controls [36].
Integra is a semibiologic bilayered dressing composed
of a matrix of type I bovine collagen, chondroitin-6-
sulfate, a glycosaminoglycan from shark cartilage, under a
temporary silicone epidermal sheet [29, 37]. The pore size
(70–200μm) is designed to allow migration of the patient’s
own endothelial cells and ﬁbroblasts. As the wound heals,
the silicone sheet is removed and a thin autograft is grafted
onto the neodermis to complete the wound coverage. It is
indicated for excised deep partial- and full-thickness burn
wounds. Additionally, in nonburn wounds it is used in
complex traumatic soft tissue reconstruction over exposed
tendons, joints, and bone, as well as wounds from vascular
and pressure ulcers [38]. A study with 10-year followup
shows excellent cosmesis, with higher patient satisfaction
than autologous skin grafting alone and with excellent
mobilitywhenplacedoverjoints[35].Inchildreninvolvedin
the study, the product was able to grow with the child. Jeng
et al. [39] describe their 7-year experience with 44 patients
using Integra to cover soft tissue defects over exposed bone,
tendon, and joints, often using multiple serial layers of
Integra to ﬁll in large depressions. They have had overall
good results and feel they have potentially saved several
extremities that otherwise would require amputation.
6.GrowthFactorsandBiologicWoundProducts
B i o l o g i cw o u n dp r o d u c t sh a v eb e e na na r e ao ft r e m e n d o u s
growth as our understanding of the details of the wound
healing response has increased. In normal wound healing
there is an orderly, predictable sequence passing through
the inﬂammatory, proliferation, and remodeling/maturation
phases. This process is driven by numerous cellular medi-
ators including eicosanoids, cytokines, nitric oxide, and
various growth factors. The ﬁeld of biologic wound products
aims to accelerate healing by augmenting or modulating
these inﬂammatory mediators. While the majority of inves-
tigations on these substances are small laboratory studies,
there are some clear beneﬁts seen in clinical investigations.
Eicosanoids are arachadonic acid metabolites including
prostaglandins, prostacyclines, thromboxane, and leuko-
trienes. They primarily aﬀect the early stages of wound heal-
ing including initial vasoconstriction and later vasodilation,
vascular permeability, and inﬂammatory cell chemotaxis
and adhesion. The most well known is prostaglandin E1
which inhibits platelet and neutrophil activation, reduces
blood viscosity, stimulates tissue plasminogen activator
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smooth muscle [38]. Because of this ability to modulate
inﬂammation and vasodilate, its use in chronic vascular
ulcers has been evaluated with some signiﬁcant decrease in
size and healing time compared to controls [38, 39].
Cytokines regulate inﬂammation by inﬂuencing
hematopoietic cells and include chemokines, lymphokines,
monokines, interleukins, colony-stimulating factors, and
interferons. Several of these have been studied. Interleukin-
1, which stimulates most cells in the wound environment,
was tested in pressure ulcer patients with equivocal results
[40]. Granulocyte/macrophage colony-stimulating factor
(GM-CSF) has been most extensively studied. Its eﬀects
are to stimulate neutrophils, macrophages, keratinocytes,
and ﬁbroblasts and increase VEGF production, rendering
it a very promising molecule in wound healing [41]. There
have been encouraging results in a prospective randomized
control study involving patients with venous stasis ulcers
[42], as well as studies on diabetic-foot ulcers [43].
Growth factors stimulate mainly ﬁbroblasts and ker-
atinocytes via transmembrane glycoproteins [44]. They
have been studied more than any other biologic wound
supplement. They are divided into ﬁve superfamilies, the
most known being the platelet-derived growth factors.
Recombinant PDGF was studied in a series of 118 patients
with diabetic-foot ulcers by Steed et al. [45]. Patients were
treated with rhPDGF or placebo for up to 20 weeks in this
prospective randomized double-blind study. The rhPDGF
group showed a statistically signiﬁcant higher percentage of
patients that achieved wound healing, 48% versus 25%, as
well as a greater reduction in wound size. This study helped
lead to FDA approval of rhPDGF for diabetic ulcers, which
is now known as becaplermin, with its trade name being
Regranex. It is the only current FDA-approved product in
the growth factor family. Additional studies have conﬁrmed
increased odds of wound healing and decreased rates of
amputation in diabetic foot ulcers [46], as well as accelerated
wound healing in abdominal wound separation [47]a n d
irradiated wounds [48].
7. HyperbaricOxygen
Hyperbaric oxygen is a treatment modality that has been
used as an adjunct in wound healing for 40 years. It involves
placingthepatientinasealedchamberwhere100%oxygenis
pressurizedtobetween1.5and3atmospheresabsolute(A T A)
for 60 to 120 minutes over a course of multiple treatments.
Originally designed for use in decompression illness in deep
sea divers, it has indications for use for carbon monoxide
poisoning, crush injuries, compartment syndrome, acute
traumatic ischemia, ischemia-reperfusion injury, radiation
injury, compromised skin grafts, infections with anaerobic
organisms, and refractory osteomyelitis. In addition, there
are some speciﬁc indications for HBO therapy in chronic
wounds [49].
Hyperbaric oxygen has few absolute contraindications.
Reactive airway disease, untreated pneumothorax, and con-
current chemotherapy are absolute contraindications due
to air trapping, potential for tension pneumothorax, and
increased morbidity with chemotherapy [49]. Adverse reac-
tions include otic or sinus discomfort, claustrophobia, and
neurologic oxygen toxicity seen at high pressures. This can
be reduced by providing air breaks during treatment.
T h em e c h a n i s mo fa c t i o no fh y p e r b a r i co x y g e ni s
not clearly understood, but several studies are currently
ongoing. Initial theories focused on increases in oxygen
availabilityatthetissuelevel[49].Theincreasedatmospheric
pressure increases arterial oxygen pressure (PaO2), which in
turn causes vasoconstriction. This vasoconstriction on the
arterial end reduces capillary pressure, which promotes ﬂuid
absorption into the venous system thereby reducing edema,
as well as causing an increase in hyperoxygenated plasma to
the tissues. This eﬀect typically lasts for several hours after
the treatment has ﬁnished [50]. Tissue repair processes such
as collagen elongation and deposition and bacterial killing
by macrophages are dependent upon oxygen, so increased
levels, especially in wound areas that already have impaired
perfusion, serve to facilitate wound healing.
On a molecular level, recent studies have focused on
the eﬀects of hyperbaric oxygen on neovascularization of
diabetic wounds. Angiogenesis refers to the ingrowth of
new vessels into a wound from the surrounding tissue.
Vasculogenesis is the process whereby progenitor stem cells
diﬀerentiate and reform a vascular network within a wound
[51].Theseprocessesareimpairedinthediabeticpatient,but
evidence suggests that hyperbaric oxygen can help improve
these pathways.
Neovascularization in wounds is dependent upon two
main processes [52]. First-endothelial progenitor cells
(EPCs) and other stem cells are mobilized from the bone
marrow into the circulation. Elevated systemic levels of these
cells must then interact with appropriate local wound factors
andcytokines,namely,stromal-cell-derivedfactor(SDF)-1α,
in order to stimulate vasculogenesis. Diabetic patients have
been shown to have decreased numbers and impaired func-
tion of bone-marrow-derived EPCs [53, 54], and impaired
EPC recruitment [55]. Hyperbaric oxygen is shown to
stimulate EPCs and stem cell release from bone marrow
both by increased cell proliferation within the marrow, as
well as by rapid mobilization via matrix metalloprotease
mechanisms [56–58]. This appears to be mediated through
nitric oxide pathways [57]. The stimulation of nitric oxide
pathways by hyperbaric oxygen is also supported by several
studies of HBO in ischemia-reperfusion injury [59–61].
Initial studies on hyperbaric oxygen showed reduced
sizeofchroniclower-extremitywoundsininsulin-dependent
diabetics [62]. A 2004 Cochrane evaluation of HBO therapy
in chronic wounds looked at randomized controlled trials
comparing HBO to no-HBO treatment [63]. They found a
total of 5 studies that met inclusion criteria. 147 patients
in four studies dealt with diabetic-foot ulcers, and the
results showed a signiﬁcant decrease in the rates of major
amputations, as well as an increase in the number of wounds
that remained healed 1 year posttreatment. The ﬁfth study
of 16 patients showed a decrease in the size of venous
ulcers at 6 weeks. An additional study comparing lower-
extremity wounds treated by HBO, standard wound care,
growth factor therapy, or HBO plus growth factor therapy6 Plastic Surgery International
showed a signiﬁcant increase in healing at 8 weeks in the
HBOgroupcomparedtothestandardcareandgrowthfactor
groups, with no additional beneﬁt being seen by the HBO
plus growth factor group [63].
MorerecentlytheHyperbaricOxygenTherapyinDiabet-
icswithChronicFootUlcers(HODFU)studywascompleted
[64]. This randomized, double-blinded, placebo-controlled
study compared between Wagner grade 2, 3, or 4 chronic
ulcers treated with hyperbaric oxygen or hyperbaric air.
This study found statistically signiﬁcant improvement in
wound healing at 1 year with hyperbaric oxygen (52% versus
29%, P = 0.03), with even better results in those patients
completing >35 sessions (61% versus 27%, P = 0.009).
In analysis the largest diﬀerence in healing rate was seen
after 9 months. This corresponds with a previous RCT study
showingnosigniﬁcantdiﬀerenceinHBO-treatedgroupsat6
weeks, but achieving statistical signiﬁcance in wound healing
a t1y e a r[ 65]. This suggests that in addition to immediate
assistance in healing, hyperbaric oxygen also has a role in
long-term wound improvement, perhaps as the full eﬀects
of neovascularization are realized. More studies are needed
to delineate these mechanisms.
8. Conclusion
The ﬁeld of wound care is ever expanding with advances
in technology. While there is still no superior substitute
for reconstruction using patients’ own tissues and carefully
thought-out reconstructive procedures; new products can
help facilitate eventual healing by providing prophylaxis
against barriers to healing, augmentation of wound healing
factors, assistance in temporizing and bridging time to
deﬁnitive repair, and optimization of the ultimate results
of wound reconstruction. Current wound healing products
and modalities increase the armamentarium of the wound
practitioner to address all aspects of wound care.
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